Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for fatigue in multiple sclerosis
IRCT20230802059008N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Aspirin 325 mg daily with Placebo daily (2 arms). Primary endpoints: Fatigue of the patient, Fatigue Severity Scale and 1 more. Started Aug 2023; status: completed.
02
Drugs
aspirin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20230802059008N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230802059008N1.